News Releases
- Algernon Pharmaceuticals Announces Enrollment of Final Patient in its Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19 November 30, 2020
- Algernon Pharmaceuticals Announces 154 Patients Enrolled in its Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19 November 23, 2020
- Algernon Pharmaceuticals Announces Receipt of Refundable Tax Credit from Australian Clinical Research November 16, 2020
- Algernon Pharmaceuticals Provides Update on its Ifenprodil Phase 2 Clinical Trials Featured on BioPub Webcast Hosted by Dr. KSS MD PhD November 13, 2020
- Algernon Pharmaceuticals Announces Plans to Provide Interim Data from its Ifenprodil Phase 2b/3 COVID-19 Human Study November 9, 2020
- Algernon Pharmaceuticals Announces Green Light From Data and Safety Monitoring Board to Continue its Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 October 30, 2020
- Algernon Pharmaceuticals Announces 25% Enrollment in its Ifenprodil IPF and Chronic Cough Phase 2 Human Study October 13, 2020
- Algernon Pharmaceuticals Appoints Dr. Mark Swaim MD, PhD to its Medical and Scientific Advisory Board October 9, 2020
- Algernon Announces 75% Enrollment in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 October 2, 2020
- Algernon Announces Enrollment of 100 Patients in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 September 29, 2020